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New techniques are required for earlier diagnosis and response to treatment of            
pancreatic cancer. Here we report a label-free approach in which circulating pancreatic            
tumor cells are isolated from healthy peripheral blood cells via cell bioimprinting            
technology. The method involves pre-fabrication of pancreatic cell layers and a           
sequential casting the cell surfaces with series of custom-made resins to produce            
negative cell imprints. The imprint functionalized with a combination of polymers to            
engineer a weak attraction to the cells which is further amplified by the increased area               
of contact with the matching cells. A flow-through bioimprint chip was designed and             
tested for selectivity towards two pancreatic tumor cell lines, ASPC-1 and Mia-PaCa-2.            
Healthy human peripheral blood mononuclear cells (PBMCs) were spiked with          
pancreatic tumor cells at various concentrations. Bioimprints were designed for          
preferential retention of the matching pancreatic tumor cells and with respect to            
PBMCs. Tumor bioimprints were capable of capturing and concentrating pancreatic          
tumor cells from a mixed cell population with increased retention observed with the             
number of seedings. ASPC-1 bioimprints preferentially retained both types of          
pancreatic tumor cells. This technology could have relevance to collection and           





Patients diagnosed with pancreatic cancer will most likely die within a year irrespective of              
treatment [1,2]. It has the lowest survival by stage of any other solid tumor [3]; a 10-year                 




non-surgically resected patient survived beyond 5 years [4]. A comprehensive review of 37,000             
hospital cases of PC has also shown overall survival of only 0.41% [4]. This high mortality is                 
mainly because of the propensity of the tumor to early metastasize and spread [5] and even the                 
smallest primary lesions often show perineural and lympho-vascular invasion [6]. More           
recently, the 5-year survival rates have improved slightly but differs from country to country,              
based on management approaches such as early surgical removal, stage, absence of lymph node              
metastasis. Worldwide, survival is generally around 5% [2] and it is the fifth most common               
cause of cancer death in the UK [7] and Europe [8]. In the U.S, PC is the fourth leading cause of                     
cancer death [9] and second most common gastrointestinal malignancy. Surgical resection of the             
tumor is associated with the best patient outcomes but as stated above due to early tumor spread                 
this is not an option in many cases.  
Pancreatic cancer is a malignancy that is very difficult to detect early, it is rarely cured (less than                  
1%) and even small tumors have often metastasized early to the liver [10]. This is preceded by                 
release of circulating tumor cells (CTCs) which spread to the patients organs through the              
peripheral blood circulatory system [11 ,49]. Pancreatic CTCs can be used as a biomarker for               
potential earlier detection of cancer [12] however, there is no proven technology which could              
capture and detect these cells [12-14]. CTCs usually have oval shapes within the blood and there                
are size and shape differences between the pancreatic tumor cells and normal blood cells, which               
allows the latter to be selectively targeted by cell shape recognition. These features may              
potentially allow pancreatic CTCs to be extracted from blood samples by cell shape and size               
recognition using bioimprints produced for these specific types of cells. Available methods for             
the collection or detection of CTCs take advantage of various physical properties of the target               
cells and their surfaces [15-24].  
Bioimprints have recently been recognized for their great potential for biomedical diagnostics            




isolating them or delivering biocides directly to their surface [25-27]. Bioimprints are exact             
physical copies of the surface of a cell layer which can be produced by impressing the cells with                  
a layer of curable polymer or other material [25, 27-29]. The bioimprinting process produces a               
polymeric cast of the whole cell layer, producing a negative replica of the cells shape and size                 
[25, 28, 29,50]. When a matching cell comes in contact with the bioimprint, it becomes strongly                
attracted to its surface, as the bioimprint-cell attraction is amplified by the increased contact area               
which results in cell shape and size recognition [30]. Dickert ​et al​.[31] pioneered a soft               
lithographic technique by imprinting whole yeast cells on the sensor surface of a quartz crystal               
microbalance (QCM) which allowed selective capture of different types of yeast. Similar            
approaches have been recently developed for detection of bioparticles [32], viruses [33], bacteria             
[34] and human cells [35]. Bioimprint binding of rod-like and oval-like shaped bacteria has also               
been demonstrated [36]. More complex techniques [37] involved a combination of cell-imprints            
combined with affinity ligands to trap microorganisms by simultaneous shape/size recognition           
and surface affinity. Whole cell imprinting has gained traction for development of specific             
probes for concentration and identification of microorganisms in aqueous samples [34,38]. Jenik            
and co-workers [39] reported blood cell bioimprints that allowed identification of different            
blood groups.  
Recently, bioimprinting technology was developed to produce colloid antibodies, which use cell            
shape recognition to selectively target microbial cells of specific shape [26,27]. Furthermore,            
Das ​et al​. [28] successfully developed bioimprinting technology to separate leukemic           
myeloblasts from healthy peripheral blood cells. A promising approach for targeting specific            
blood cancer cells and their separation from peripheral blood based on generic bioimprints has              
also been recently reported [25, 28, 29]. Personalized bioimprints that may have the potential to               
target specific cell types and do not require major morphological differences from healthy cells              




In the present study, we focus on developing bioimprints from pancreatic tumor cells which can               
selectively attract CTCs of matching shape, size and morphology. Most CTCs have an oval              
shape, different average size and morphology than healthy circulatory cells. The use of tumor              
cell bioimprints allowed for a device to be designed for concentrating and extracting tumor cells               
from healthy blood cell samples which could see a novel approach for collecting liquid biopsies               
to isolate CTCs that can then be used for early detection of pancreatic cancer.  
 
Figure 1. ​Optical and fluorescence microscope images of (A,B) ASPC-1 cells (pancreatic tumor             
cells) and (C,D) normal peripheral blood mononuclear cells (PBMCs) suspended in PBS buffer.             
Note that the ASPC-1 cells in suspension are all spherical in shape but differ significantly in size                 
and morphology from the PBMCs. (E) Principle of action of our bioimprint-based device for              
concentrating of circulating tumor cells (CTCs) from blood samples of patients with pancreatic             
cancer. The bioimprint has several orders of magnitude higher selectivity to the pancreatic CTCs              
then for normal white blood cells based on their interaction with a bioimprinted surface. The               
imprint binds the CTC cells that fit closely into the casted cell shapes on its surface more                 
strongly than the PBMCs. The cell shape recognition amplifies the CTCs attraction to the              
bioimprint. (F) Schematics of the bioimprint chip. 
 
Pancreatic cancer liquid biopsies present an ideal target for cell recognition by prefabricated             
bioimprints where a very strong specific adhesion can occur between the bioimprint and tumor              
cells within a sample containing cells of matching shape. Here we investigate a novel ​in vitro                
approach for liquid biopsies based on bioimprinting technology which would potentially allow            




preparation of bioimprints of pancreatic tumor cell lines and using these to develop a device for                
capturing and interrogating tumor cells. The technology may potentially be used either for direct              
capture and interrogation of pancreatic tumor cells or monitoring of cancer progression. The             
bioimprint-based approach is expected to enhance the potential for providing minimally invasive            
contemporaneous information on tumor biology prior to each planned line of molecular            
treatment, as these become available. The paradigm of the liquid biopsy is already becoming              
clinical practice in lung cancer for the assessment of EGFR mutations. Being able to study the                
whole cells rather than circulating cell free DNA [17,18] has great advantages as they provide a                
more specific picture of therapy related changes. Data obtained can shed further light into the               
biology of pancreatic cancer, such as the nature of stem cells and the interactivity of tumor cells                 
with the coagulation pathway. 
The extraction of tumor cells from blood is possible due to the distinct cell size and                
morphological differences between the pancreatic tumor cells and normal blood cells (PBMC) -             
cf. Figure 1A,B with Figure 1C,D. The principle action of the device is illustrated in Figure                
1E-F and relies on the increased area of contact of the target cells with the bioimprinted surface                 
upon cell shape recognition. The latter is based on amplification of the cell adhesion when the                
imprint surface is approached by cells of matching shape and size in near vicinity and can                
increase the binding energy of even a weak cell-surface attraction by several orders of              
magnitude. Since normal white blood cells are much smaller and different in morphology to              
tumor cells, this result in much higher cell shape-specific retention of the latter on the bioimprint                
surface. Note that the cell recognition here relies of physical cell shape and size replication               
rather than bio-molecular recognition based on much more expensive antibodies [25]. Rhim et             
al. [48] recently reported pancreatic CTCs invade and enter the bloodstream unexpectedly early,             
before malignancy could be detected by rigorous histologic analysis which is widely associated             




mesenchymal phenotype, exhibited stem cell properties, and seeded the liver [48]. Along this             
line, here we explore how universal is the pancreatic tumor bioimprint fabricated using             
secondary tumor cells (ASPC-1) in capturing pancreatic tumor cells generated by a primary             
tumor of similar phenotype (Mia-PaCa-2). Preparation of a universal, generic negative           
bioimprint of a widely pancreatic tumor cell line would allow potential isolation of any patient               
CTCs of the same type and collection of liquid biopsies that may facilitate early diagnosis.  
 
Figure 2. The effect of fixation on the tumor cell dimensions. Brightfield optical microscopy              
images of ASPC-1 fixed (A) and live cells (B); Mia-PaCa-2 fixed (C) and live cells (D). The cell                  
diameter distributions were analyzed by Mastersizer before fixation (Red dashed line) and after             
fixation (Black line) with 0.5% glutaraldehyde (E,F). The cell size distributions of the two types               
of pancreatic tumor cell lines are compared in (G) for fixed and (H) for live cells. 
 
2. Results and Discussion 
2.1 Cell fixation and staining 
In order for a bioimprint to be able to effectively distinguish and capture the cells of interest                 
there must be a measurable size and shape difference between the target cells and other cells                
within a mixed cell population. Also, effective staining of the target cells is required in order to                 
be able to quantify the capture efficiency of the bioimprints. To achieve this ASPC-1 cells were                
stained with carboxyfluorescein-lipid conjugate and PBMC were stained with lissamine          
rhodamine. Light and fluorescence microscopy showed both effective staining of ASPC-1 and            




a high throughput and multiple repeat experiments in this exploratory study, cells were fixed              
prior to testing. This was done to avoid uncontrollable change of the cell morphology and size as                 
a fraction of them may lose their viability in the course of the experiments which may affect                 
their interactions with the bioimprints. The effect of cell fixation therefore is important in terms               
of potential altering of the cell dimensions. To investigate the magnitude of this effect, the cells,                
either live of fixed, were analyzed using a Matersizer. The data obtained suggests a negligible               
effect on cell dimensions after fixation, all cells were very slightly smaller (see Figure 2 and                
Table 1). Mia-PaCa-2 were the larger cells with a mean live cell size of ​(live 20.7 ​µ​m; fixed 18.7                       
µ​m) then ASPC-1 (live 16.3 ​µ​m; fixed 16.2 ​µ​m ​). By comparison, PBMCs showed a mean                       
diameter of 8.6 ​µ​m ​for the fixed cells and 9.2 ​μ​m ​for the live cells. All cells were normally                         
distributed suggesting that a very little overlap exists between the pancreatic tumor cells and              
PBMCs in terms of cell size (see Figure 1C, D). 
Table 1. ​ ​Volume weighted mean​ ​diameter of fixed and live ASPC-1 and Mia-PaCa-2 cells. 
Type of cells ASPC-1 Mia-PaCa-2 
Fixed 16.3 ± 1.6 18.7 ± 0.14 
Live 16.2 ± 0.3 20.7 ± 1.3 
 
 
2.2 Bioimprint fabrication 
The protocol for fabrication of the bioimprints used is schematically presented in Figure 3A.              
The cell templating method is similar (but not identical) to the replication of the surface of                
particle monolayers in the Gel Trapping technique [40-45] and the associated fabrication of             
micro-lens arrays from particle monolayers [46]. The pancreatic tumor cell suspension was            
mixed with glucose and xanthan gum as a viscosity modifier and spread over a glass substrate                
pre-coated with a cationic polymer (PDAC). The role of the glucose was to fill the voids                




polyurethane (PU)) from penetrating into the voids of the cells multilayer. After curing, the              
PDMS negative imprint was peeled off, cleaned from any cell residues by using adhesive tape               
and then treated with a diluted hydroxypropyl methyl cellulose (HPMC) aqueous solution in             
order to form a molecular layer of adsorbed HPMC which facilitates the detachment of the               
further templated copies of the bioimprint [28]. Then the PDMS bioimprint was templated again              
with a UV curable PU resin to produce a master positive imprint on polyethylene terephthalate               
(PET) foil. The latter was used to create multiple identical negative imprints on PET using other                
resins (UV curable acrylic resins or PU resin) with HPMC treatments in between. Although our               
method uses cell multilayers as a starting template, the cells are pre-fixed with glutaraldehyde              
which limits their deformability in the multilayer. The templating process with PDMS            
practically casts only the shape of the top cell layer and the presence of other cells underneath                 
has no effect on the shape of produced imprints. This simplifies the process as it does not require                  
fabrication of a perfect cell monolayer. 
 
 
Figure 3 ​. (A) Schematic of the preparation of cell imprints using a layer of pancreatic tumor                               
cells templated with curable silicone. The bioimprint retains information about the blood cancer                         
cells shape and morphology, can be reproduced on a large scale and used in pancreatic tumor                               
cell concentrator device for early detection of pancreatic cancer. (B) Surface treatment of the                          




polyelectrolyte allows us to promote adhesion between the bioimprint and the shape matching                         
tumor cells. 
 
Figure 3B illustrates the surface treatment of the negative bioimprints before being used in the               
flow-through chip. The imprint was surface oxidized with oxygen plasma to create abundant             
carboxyl groups (-COOH) on its surface which then serve as anchoring points of a cationic               
polyelectrolyte (branched polyethylene imine, bPEI). The purpose of this treatment was to            
engineer a weak electrostatic attraction between the imprint surface and the negatively charged             
cells (PBMCs and CTCs). ​Although curable PDMS has a good resolution to retain the molded                         
shape of the cell layer, it has very poor retention of any surface groups like COOH, resulting                                 
from surface oxidation. The reason is the inherent fluidity of the silicone chains trapped in the                               
3D network of the cured PDMS, leading to gradual transfer of COOH groups from the surface to                                 
the bulk. It has been reported that surface oxidised PDMS increases its contact angle over the                               
course of several hours [60,61]. This is why we use PU resin replica which preserves its surface                                 
properties after surface oxidation due to the rigid 3D structure of this polymer. In addition the                               
PU resin is harder than the PDMS which helps with the replication process. 
To prevent both types of cells from coming too close to the imprint and becoming trapped by the                                   
van der Waals attraction, we treated the bPEI coated imprint with an additional layer of Pluronic                               
surfactant (Poloxamer 407) which minimizes non-specific attachment of the cells to the imprint                         
[28,29]. The effect of the Poloxamer 407 treatment is not related to changing of the wettability                               
of the bioimprint surface rather than off-setting the cells from the surface which prevents                           
non-specific adhesion [28,29]. The idea behind this combination of treatments is that when the                           
approaching cells match closely the imprint cavities, the weak electrostatic attraction is                       
amplified by the large area of contact with the imprint cavity. For PBMCs, which do not closely                                 




removal from the imprint while the CTCs remain on the imprint and concentrate on its surface,                               
which facilitates their detection.  
2.3 Bioimprint microscopy characterization 
 
As the cell dimension analysis appeared ideal for bioimprint separation the tumor cells were              
used to create a bioimprint as a negative replica of the top surface of a layer of tumor cells.                   
Figure S1A,B (Supporting Information) shows the initial cell layer of ASPC-1 cells before the              
replication process. A PDMS replica of this layer was produced. The cell layer remained mostly               
intact (Figure S1D) after replication with PDMS (Figure S1C) as most cells remained attached              
to the glass substrate due to the adhesion of the glucose and xanthan gum additives. The                
negative PDMS imprint in turn was then used to create a positive master PDMS imprint (Figure                
4A,B). From this master imprint, multiple copies could be made using UV curable PU resin and                
these were then analyzed and used in our experiments. Analysis showed that there was no               
significant loss of quality of the bioimprint from the first negative (Figure 4A) to the               
consecutive negative imprints (Figures 4E, F) taken by templating the master positive imprint             
(Figure 4B, 4C) on PDMS and the one based on PU-resin on PET foil (Figure 4D).  
Figure S2 (Supporting Information) shows further optical microscopy images of the negative            
and positive imprints of ASPC-1 cell layers which indicated a good quality of the replication               
process. Figure S8 shows more SEM images of ASPC-1 negative imprints on PU resin copied               
from a PDMS positive imprint of a layer of the same cells. Figure S3 shows similar quality of                  
the replication of Mia-PaCa-2 cell layers by PDMS as negative (Figure S3A), positive master              
(Figure S3B) and negative imprints on PU resin on PET foil, which was used in our                
experiments. Figure S4 shows SEM images of consecutive negative replicas of the master             
PDMS imprints indicating that multiple negative imprints can be taken without loss of quality or               
resolution. 




A series of experiments was undertaken to determine the bioimprint cell selectivity for the target               
tumnour cells within a mixed cell population. To investigate the capture efficiency of pancreatic              
tumour cells a series of ASPC-1 or MiaPaCa-2 cell concentrations were added to healthy human               
(PBMC) to create a mixed cell population. Firstly, the capture of ASPC-1 cells on an ASPC-1                
bioimprint was investigated. The capture efficiency (percentage of ASPC-1 retained on the            
bioimprint with respect to the PBMC population) was observed to be proportional to the initial               





Figure 4. SEM image of the PDMS negative bioimprint of ASPC-1 cell layer (A). SEM images                
of the PDMS positive bioimprint of ASPC-1 cell layer at different resolutions (B,C). SEM              
image of the positive ASPC-1 bioimprint on PU-resin on PET foil (D) copied from the negative                
PDMS bioimprint (A). SEM images of a negative PU resin on PET bioimprint at different               
resolutions (E,F) copied from the positive PDMS bioimprints (B,C)​.  
 
 
Figure 5A and 4C show flourescence microsopy images after seeding of a 1%:99%             
ASPC-1:PBMC cell mixture on the bioimprint chip. Figures 5B and 5D show the retained              
PBMC and ASPC-1 cells after incubation and flushing with 150 mL h​-1 PBS. Data obtained with                
single seeding at 1% ASPC-1 initial concentration showed that only ~30% of the initial amount               
of tumor cells were retained on the bioimprint chip after the flushing step. However, at 5%                
ASPC-1, neary 90% of the tumor cells were retained on the imprint after a single seeding on the                  
chip (Figure 5E). At 1% initial ASPC-1 concentration with respect to the PBMCs, the retained               





Figure 5. Fluorescence microscopy images of lissamine-rhodamine stained PBMC on an           
ASPC-1 PU negative bioimprint at time of seeding (A) and after flushing with PBS (B).               
Fluorescent microscopy images of carboxyfluorescein-lipid stained ASPC-1 cells on an ASPC-1           
PU bioimprint at time of seeding (C) and after washing (D). The percentage of retained ASPC-1                
cells with respect to the PBMC (E) and (F) with respect to the initial percentage of ASPC-1 cells                  
versus the percentage of ASPC-1 cells in the initial seeding mixture. Each data point is an                
average of at least 2 repeats. Pearson’s rank correlation coefficient (r) was 0.98 (E) and -0.99                
(F). 
 
SEM images captured after the retention experiments showed the larger tumour cells and PBMC              
clearly retained on the bioimprint. Figure 6 presents SEM images of the ASPC-1 bioimprint              






Figure 6. ​SEM images of ASPC-1 cell bioimprint after incubating with PBMC:ASPC-1 cell             
mixture under static conditions. Non-bound cells were flushed from the surface by PBS buffer at               
fixed flow rate of 150 mL h​-1 which selectively washes the PBMCs. The SEM images were                
taken after drying at different resolutions (A, B). Note the difference is size and morphology of                
the ASPC-1 cells and the PBMCs (even after shrinking during the drying process for SEM               
sample preparation (C). 
 
One can see that although the cells have partically shrunk due to drying during the the sample                 
preparation for SEM, there are clear morphological and size differences between the tumor cells              




perceived that the increased area of contact between the matching tumor cells and the imprint               
surface makes them more strongly attached to the bioimprint and thus allows them to be retained                
on the chip after the flushing step. This depletes a much higher fraction of PBMCs leading to                 
effective concetrating of the captured tumor cells in proportion to the PBMCs on the bioimprint. 
Multiple seedings of different types of tumor cells on the ASPC-1 and MiaPaCa-2 bioimprints              
were assesed to ascertain whether this would result in capture of more tumour cells. The data in                 
Figures 7A obtained on ASPC-1 bioimprint suggests a gradual increase from 34% to 55% in the                
retained cell ratio of ASPC-1:PBMC with multiple seedings again showing an amplification of             
the target tumor cell population.  
A gradual decrease in the retained PBMCs percentage on the imprint was observed with each               
seeding and the ASPC-1 bioimprint was enriched with tumor cells (Figure 7B). The trend was               
even stronger for Mia-PaCa-2 cells on Mia-PaCa-2 bioimprint (see Figure 7C and 7D). To              
further assess the selectivity of the larger tumour cells over PBMCs, Mia-PaCa-2 cells were              
seeded onto the ASPC-1 bioimprint and the data obatined were shown to be similar (Figure               
7E,F). Interestingly, the seeding of Mia-PaCa-2:PBMC cell mixture on ASPC-1 bioimprint           
produced very similar results as ASPC-1:PBMC mixture on ASPC-1 bioimprint (Figure 7A,7B)            
with an initial retention ratio of 28%:72% of Mia-PaCa-2:PBMC, increasing to 52.5%:47.5%            
after the 5th seeding. Since ASPC-1 and Mia-PaCa-2 are geometrically and morphologically            
very similar (see Table 1 and Figure 2) one would expect that the bioimprint, produced from one                 
pancreatic tumor cell line could be effective for capturing other pancreatic CTCs of the same               
geometry and morphology. This presents an opportunity to produce a generic bioimprint from a              







Figure 7. (A) ASPC-1 cells and (B) PBMCs retention on an ASPC-1 bioimprint in relation to                
the number of individual seedings of the cell mixture on the bioimprint. The seeding cell ratio in                 
(A,B) was 0.5% ASPC-1:99.5% PBMC. (C) Mia-PaCa-2 cell and (D) PBMC retention on an              
Mia-PaCa-2 bioimprint in relation to the number of individual seedings of the cell mixture on               
the bioimprint. (E) Mia-PaCa-2 cells and (F) PBMCs retention on an ASPC-1 bioimrpint as a               
function of the number of individual seedings of the cell mixture on the bioimprint. The seeding                
cell ratio in (C-F) was 0.5% Mia-PaCa-2:99.5% PBMC. Each data point is an average of at least                 
2 repeats. Pearson’s rank correlation coefficient (r) was 0.89 (A), -0.89 (B), 0.98 (C), -0.98 (D),                
0.98 (E) and -0.98 (F). 
 
Althougth the bioimprint chip is far from optimized to be a direct CTCs early detection tool,                
these results are very encouraging and when used with a CTC enrichment step could allow for                
liquid biopsy analysis from patient samples and increase the likelihood for early detection of the               
primary tumor. ​Figure 8A, 8B shows the effect of the interchangeability of the type of the                             
pancreatic tumor imprint on its capture efficiency. The images show the effect of multiple                           
seedings of a mixture of Mia-PaCa-2:PBMC cell mixture (0.5%:99.5%) on the retained cells                         
after flushing of the bioimprint chip with PBS. Note that the percentage of decrease of the                               
initially seeded tumor cells after flushing initially decreases with the number of seedings from                           




mixture (Figure 8C). Note that accumulation of the Mia-PaCa-2 cells during this process, as                           




Figure 8. Fluorescence microscopy image of a mixture of 0.5% Mia-PaCa-2 and 99.5% PBMC              
on ASPC-1 bioimprint after the 1​st seeding (A) and after the 5​th seeding (B) followed flushig of                 
the chip with PBS at 150 mL h​-1​. The fluorescence microscopy images are superimposed on the                
brightfield images of the ASPC-1 bioimprint. The corresponding percentage of decrease of            
Mia-PaCa-2 cells (C) and PBMCs (D) in relation to the number of individual seedings of the cell                 
mixture on the ASPC-1 bioimprint. The seeding cell ratio in (A,B,C,D) was 0.5%             
ASPC-1:99.5% PBMC. The retained percentage of Mia-PaCa-2 cells (with respect to the            
PBMCs) as a function of the initial cell percentage (E). The relative percentage of ine initial                




bioimrpint (F). Pearson’s rank correlation coefficient (r) was -0,66 (C), 0.01 (D), 0.98 (E) and               
0.14 (F). 
We did not detect a measurable effect of the seedings on the percentage decrease PBMCs, which                               
was consistently high for all seedings (~99.5%), indicating that PBMCs are not preferentially                         
retained on the ASPC-1 imprint (Figure 8D). Increasing the initial Mia-PaCa-2 cell percentage                         
generally led to an increase of the percentage of cells retained on the imprint (Figure 8E). We                                 
found that this increase is in fact proportional to the initial percentage of tumor cells as the ratio                                   
of the percentage of the retained Mia-PaCa-2 cells towards their initial percentage (with respect                           
to the PBMCs) does not change (Figure 8F). Additional data for the percentage of decrease and                               
retention data for ASPC-1 on ASPC-1 imprint are Mia-PaCa-2 on ASPC imprint are presented                           
in the Supporting Information (Figures S6 and S7), respectively. These results warrant                       
discussion. A recently developed technique of automated filtration of CTCs based on size and                           
using cytokeratin staining as a detection marker has been reported [16] where 42% of pancreatic                             
cancer patients had detectable CTCs.   
Similar to our methodology the authors spiked ​in vitro cultured pancreatic tumor cells into test                             
samples. Firstly they used whole blood and then separated the PBMC/CTCs by Ficoll density                           
gradient centrifugation, which the authors noted caused a loss of CTCs compared to spiking into                             
PMBCs after isolation from blood. As a result they then used an apheresate from healthy donors                               
and spiked in tumor cells. EpCAM was noted as not being useful for detection of CTCs in                                 
pancreatic cancer in the study. 
Most CTCs isolation methods do rely on enrichment via label-dependent methods, which                       
require expensive antibodies [17]. For example, a recent study used three EpCAM expressing                         
tumour cell lines of different tumours (Prostate; PC3, breast; MCF-7 and pancreatic; T24) for                           
surface replication [51]. When the surface was modified to include an anti-EpCAM antibody                         




pancreatic cancer patient CTC samples may not express EpCAM and therefore its potential use                           
as a target from patient samples may be limited. Their results also suggested that the cancer cells                                 
did not preferentially bind to their own replica imprints, as also shown here. A further study                               
from the same group [52] utilised pollen grains to produce a PDMS imprint surface, again                             
modified to include an anti-EpCAM antibody. This imprint was found to be efficient for                           
capturing EpCAM positive MCF-7 and PC-3 cells but not EpCAM negative HeLa, Jurkat or                           
Daudi cells suggesting the use of EpCAM was crucial to cell capture unlike in the present study                                 
where imprinted cell morphology and chemical surface modification was used to effectively                       
target tumour cells over non-tumour cells. A further study, utilising cell imprinted gelatin                         
substrates also used EpCAM to capture MCF-7 cells selectively [53]. To functionalise the                         
imprint surface however, is costly but could also lead to further discrimination between tumour                           
and non-tumour cells. 
Other methods are label-free such as bioimprinting and filtration methods which have the                         
advantage of simplicity and lower cost. Out of all these current methods, only bioimprinting can                             
mimic the target cell morphology in a precise manner, while other techniques rely on filtration                             
pore size and cell deformability to achieve enrichment. Gao et al have previously demonstrated,                           
using PDMS imprints of a breast cancer cell line (MCF-7) that imprints not only accurately                             
mimicked cell morphology but the cell-imprinted PDMS surface also retained proteins                     
originating from the extracellular matrix. These motifs could then become artificial receptors                       
which improve the target cell retention on the imprint, by enabling adhesion of the targeted cells                               
[54]. To ascertain whether the imprints produced here can act in such a way could be further                                 
investigated using ligands to cell surface receptors and assess any specific binding. Previously,                         
Imprinting bacteria in a principle as used here led to selectivity primarily via chemical                           




The limitations with the presented bioimprint-based technique include a pre-purification step to                       
isolate the PBMCs from whole blood which, as discussed above may not isolate all CTCs                             
present although the clinical potential is clear from the results obtained within the study.                           
Furthermore, there is the possibility that the imprints produced may capture other tumour cells                           
which may pave the way for a more universal tumour imprint which would greatly enhance the                               
potential in both research and clinical practice. This universality has been investigated recently                         
with promising results small 2020 [56]. 
3 Conclusions and future outlook 
The objective of the present study was to create generic pancreatic tumor bioimprints and test               
these for selectivity of the target tumor cells over healthy human blood cells (PBMCs). ​In               
summary, we designed and manufactured a pancreatic tumor cell bioimprint from two different                         
cell lines (primary and secondary tumors) and demonstrated that both of them are capable of                             
isolating and enriching pancreatic tumor cells from healthy white blood cells. The simplicity of                           
the principle of tumor CTC isolation via morphological differences with circulating healthy                       
blood cells has been studied previously via filtration techniques but here we report selective                           
capture based on cell mimicry enhanced by bioimprint surface modification. ​The methodology                      
established is robust and reproducible and allows for multiple replica bioimprints to be created              
from a single master bioimprint. Cell retention favored the target tumor cells over PBMCs due               
to the match of their cell size and morphological properties with the bioimprint cavities. We               
found that bioimprints from Mia-PaCa-2 (primary tumor) cell line and ASPC-1 (secondary            
tumor) cell line are interchangeable and allow selective capture of the two types of tumor cells.                
The increase of the number of seedings increase the CTCs capture efficiency. Tumor cell              
retention percentage over multiple seeding showed the ratio of tumor cell to PBMC being              
retained passed 50% in both ASPC-1 and Mia-PaCa-2 after 5 seedings onto an ASPC-1              




be physiologically relevant, this amplification of over 50-fold enables the efficient detection of             
low numbers of tumor cells from a mixed cell population. Cells were fixed prior to use on the                  
imprint but there is no reason why cells obtained from patient liquid biopsies could not also be                 
fixed prior to analysis. 
The method could be further developed into a clinically relevant early detection tool. The cells                             
that are captured from bioimprint based liquid biopsy can be further analyzed either with                           
fluorescently tagged antibodies or genetically analyzed on the imprint via techniques such as ​in                           
situ fluorescent hybridization (FISH). Recent advances in FISH probes resulted in 93%                       
sensitivity and 100% specificity in detecting cancer cells in pancreatobiliary tissue [57]. Another                         
FISH analysis on isolated CTC showed a sensitivity of 88% and specificity of 90% for                             
pancreatic cancer when cells were stained with a combination of markers [58]. 
A high-throughput cell screening platform could therefore be developed which could allow large                         
areas of the bioimprint surface to be imaged and captured tumor cells interrogated. The                           
preparation of a generic bioimprint from pancreatic CTCs can be done on a very large scale in a                                   
standardized way using Roll-to-Roll Nanolithography [59] as recently done by Das et al.[28] for                           
human leukemic cells, which would allow cheap fabrication of bioimprint based screening tools                         
for detection or analysis of pancreatic tumor CTCs. Further work should also be undertaken to                             
ascertain whether CTCs from tumors of multiple origins could also be captured on a single,                             
universal tumor imprint which would substantially impact CTC detection capability. 
4 Experimental Section 
4.1 Human cells culturing and fixation 
Pancreatic tumor cells (ASPC-1 and Mia-PaCa-2) were sourced from Public Health England.                       
ASPC-1 cells were cultured in RPMI medium (Lonza, UK) while Mia-PaCa-2 were grown                         




penicillin/streptomycin (1% v/v, Lonza, UK) within a humidified 37ºC incubator in the presence                         
of 5% CO ​2​. Cells were harvested when at least 70% confluency had been achieved. Human                             
PBMCs were obtained from the National Blood Transfusion Service (UK) from anonymous                       
healthy donors with ethical approval REC 16/LO/1948 (under IRAS 214660) [47] and stored in                           
liquid nitrogen prior to use. Cells were fixed with the dropwise addition of 2.5% v/v                             
glutaraldehyde in phosphate buffered saline (PBS) to concentrated cell suspensions for 15 min.                         
Cells were then washed twice with PBS and finally re-suspended in PBS at appropriate                           
concentrations. Cells were counted with a Neubauer haemocytometer. 
4.2 Preparation of ASPC-1 and Mia-PaCa-2 negative and positive bioimprints 
The glass substrate (20 cm ​× 20 cm ​× 0.5 cm) was carefully washed with ethanol, distilled water                                   
and soap. Once dried, a 10 wt% of KOH solution in ethanol was then distributed uniformly on                                 
the clean glass for complete degreasing for 1 h. The glass was washed with deionized water and                                 
dried. 1 wt% PDAC solution was poured on the glass substrate, spread evenly over the surface                               
and incubated for 2 h. The treated glass was washed again with distilled water to remove the                                 
excess of PDAC and dried under air in a laminar flow hood for 30 min. The fixed cell                                   
suspension in PBS we centrifuged and 1 g of the pellet with the cells (wet weight) was added to                                     
a solution containing 0.4125 g of glucose and 2 mL of gum xanthan (0.1 wt%) in deionized                                 
water under stirring. The final mixture was spread evenly on the glass using a customized glass                               
spreader [28] and left to dry within a laminar flow hood for 30 min. The glass was then coated                                     
with PDMS (Sylgard 184, Dow Corning, 10:1 elastomer:cross-linker ratio) using a customized                       
square metal frame (15 cm ​× 15 cm) to contain the molding material and was covered and dried                                   
at room temperature overnight. The PDMS negative imprint was detached from the glass with a                             
scalpel and washed with ethanol, distilled water and then a soap solution. Negative bioimprints                           




resin on PET foil. JR15 is a proprietary UV curable acrylic resin (Joanneum Research FmbH,                             
Graz, Austria). To create a master positive imprint a square of the negative PDMS imprint was                               
cut out with a scalpel, carefully washed with ethanol, distilled water, soap and dried. A solution                               
of 0.1 wt% HPMC in sodium dihydrogen orthophosphate buffer (5 mM, pH 3) was spread on                               
the imprint surface. After 1 h, the imprint was washed with deionized water and dried. Then, the                                 
base of the imprint was attached on glass support with double sided tape. The glass was coated                                 
with 25 mL of PDMS and cured at room temperature with a cover during 24 h. The positive and                                     
negative bioimprint are then separated from one another. A schematic of the process is shown in                               
Figure 3. 
4.3 Fabrication of multiple negative bioimprints from positive replica 
The positive bioimprint with PDMS was carefully washed with ethanol, distilled water, soap and              
dried. A solution of HPMC 0.1 wt% in sodium dihydrogen orthophosphate buffer (5 mM, pH 3)                
was spread on the imprint. After 25 min, the imprint is washed with distilled water and dried. 1                  
mL of a 10% thiol (trimethylpropanate tris (3-mercapto propionate)) solution in polyurethane            
resin was spread on a PET foil. This solution is also spread on the positive bioimprint. The foil                  
was carefully placed on top of the imprint and a scraper was used to evacuate trapped air                 
bubbles. A glass panel was clipped on the top of the PET foil on the imprint and the resin was                    
cured under UV light (Portable UV lamp, 365 nm, 10W) for 1 h. The PET foil with the imprint                   
replica was detached from the templated imprint. Images were taken from the imprint samples              
with optical microscopy (Olympus BX-51). Scanning electron microscopy (SEM) images were           
produced after coating of the specimens with a 10 nm carbon layer. 
4.4 Cell staining for bioimprint selectivity experiments 
In order to differentiate between the tumor cells (ASPC-1 or Mia-PaCa-2) and the PBMCs, all               
cells were fluorescently tagged before mixing with other cell populations: 10 mL of fixed cells               




distilled water was added. This operation was repeated twice to wash the cells, the supernatant               
was thrown after the last centrifugation and 5 mL of deionized water was added. The tube was                 
then placed in an ultrasonic bath for 5 min to avoid cell aggregation. 500 μL of ethanol solution                  
of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N (carboxyfluorescein) (0.5 g mL​-1​) was       
added dropwise in the 10 mL tumor cell suspension under agitation to fluorescently stain the               
cells in green, detectable with FITC fluorescence filter set. 500 μL of lissamine-rhodamine (0.5              
g mL​-1 in ethanol) was used for PBMCs to fluorescently stain them in red, detectable with                
TRITC filter set. After 15 min, the solution was centrifuged 5 min at 500g. The supernatant was                 
discarded and 5 mL of deionized water was added. The tube was then placed in an ultrasonic                 
bath for 5 min. A new cell counting of the fluorescently tagged cells was made to determine the                  
concentration. All cell suspensions were kept in a fridge at 4 ​°​C in enclosed flasks wrapped with                 
aluminum foil until further use in the experiments as described below. 
4.4. Bioimprint chip preparation 
To fabricate the bioimprint chip chamber, two stripes of plastic foil (0.6 cm ​× 5 cm ​× 100 ​μ​m)                   
were cut and stacked with a double-sided adhesive tape to form a template for a channel of                 
combined thickness of 250 ​μ​m. Such channel templates were then attached to the bottom of a                
square plastic dish, with at least 3 cm space between each other. 50 mL of degassed PDMS                 
(Sylgard 184, 10:1 elastomer : cross-linker) was poured on top of these stripes followed by               
further desiccation to remove any trapped air bubbles. After curing, the PDMS layer was peeled               
off the plastic dish and cut in rectangular pieces of width 25 mm and length of 8 cm, including                   
the 5 cm channel as show in Figure 1E. ​Oxygen plasma was used to alter the hydrophobicity of                          
the polymeric bioimprint. A negative PU-PET bioimprint of ASPC-1 or Mia-PaCa-2 was treated                         
in an oxygen plasma cleaner for 3 min. A solution of 0.015 wt% branched polyethylenimine                             
(bPEI) in water was spread on the imprint. This cationic polyelectrolyte was used to promote                             




coated imprint was washed with deionized water and dried. The PDMS channel of the                           
flow-through device was perforated at both ends of the channel with a biopsy tool (3 mm) to                                 
form inlet and outlet. The PDMS channel (Figure 1E) was washed with ethanol, air dried and                               
then treated in oxygen plasma for 2 min. Rectangles of negative ASPC-1 or Mia-PaCa-2                           
bioimprint (0.6 cm ​× 4.5 cm) pre-treated as described above were cut and placed over the                               
channel aperture and a microscope slide was used as base of the chip. The assembled PDMS                               
channel and the glass slide were clamped together and left in the oven at 40°C for 30 min to seal                                       
(Figure 1E-F). The channel depth was measured to be approximately 250 ​μ​m. 100 µL of 1 wt%                                 
Poloxamer 407 (POL 407) was injected in the inlet of the PDMS flow-through chip. After 30                               
min, the bioimprint chips were flushed with 10 mL of PBS by using a syringe pump with a                                   
flowrate of 219 mL h ​-1​. At this step the local flow velocity was estimated to be 0.0406 m s​-1                                     
which corresponds to Reynolds number of 18.7 (i.e. laminar flow). We have already studied and                             
discussed the flushing conditions of our setup elsewhere [28,29] which allowed us to optimize                           
the parameters in terms of flow rate, volume of buffer flushed through the chip and the time so                                   
that we maximize the retention of the target cells with respect to the PBMCs. Here we have used                                   
these conditions without further optimization.  
4.5 Tests of bioimprint selectivity 
Different cells suspensions of pre-stained ASPC-1 (or Mia-PaCa-2) and PBMCs in PBS were                         
prepared. Each sample of fixed PBMC:ASPC-1 cell ratio was repeated at least twice, and cells                             
were placed in an ultrasonic bath for 5 min to avoid any aggregation of the cells before the                                   
experiments. Figure S5 (Supporting Information) shows the experiment a setup with chip and                         
the adjacent syringe pump for flushing with PBS. 100 µL of the mixed cell suspension was                               
injected through the inlet. Chips were covered with aluminum foil for 30 min to prevent                             




cells) and TRITC (for PBMC). Chips were flushed with 10 mL of PBS by using a syringe pump                                   
with a flow rate of 150 mL h​-1 and the effluent was discarded. The local flow velocity was                                   
estimated to be 0.0278 m s ​-1 which corresponds to Reynolds number of 12.8 (i.e. laminar flow).                               
Microscopy images were taken on multiple areas on the bioimprint (at least 10 fields of view                               
with both FITC and TRITC filter sets) after this step. Fluorescence microscopy images obtained                           
were quantitatively analyzed using ImageJ software with the macro script as described in the                           
Supporting Information for each filter set, separately. Cells were enumerated by dividing the                         
area on the imprint occupied by the respective fluorescent color over the area per single cell of                                 
this type (PBMCs or ASPC-1 or Mia-PaCa-2) determined from the mean cell size (see Figure 2).                               
The calculation of the percentage decrease of the respective type of cells after flushing of the                               
chip and the percentage of retained cells are described in the Supporting Information.                         
Experiments with multiple seedings were also undertaken where after each flushing step, a new                           
seeding with the same cell mixture was made, flushed after 30 min of incubation on the                               
bioimprint and fluorescence microscopy images were taken and analyzed. 
4.6 Statistical analysis 
Where appropriate statistical analysis was performed. Data is presented and analysed as mean                         
(±SD) from two independent repeat experiments (n=2). Pearson’s rank correlation coefficients                     
(r) were used to determine the extent of the relationships between seedings and cell counts and                               
ratios of cells seeded to that retained. These were performed using the data analysis toolpack for                               
Microsoft Excel v 16.27 for Mac. 
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